<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03594435</url>
  </required_header>
  <id_info>
    <org_study_id>18-000963</org_study_id>
    <secondary_id>R01AA026190</secondary_id>
    <nct_id>NCT03594435</nct_id>
  </id_info>
  <brief_title>Ibudilast for the Treatment of Alcohol Use Disorder</brief_title>
  <official_title>A Randomized Controlled Clinical Trial of the Neuroimmune Modulator Ibudilast for the Treatment of Alcohol Use Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>MediciNova</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a double-blind, placebo-controlled randomized clinical trial of IBUD (50mg BID)&#xD;
      for the treatment of Alcohol Use Disorder (AUD). Eligible participants will undergo a 12-week&#xD;
      medication treatment period and 5 in-person visits over 16 weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study design consists of a 12-week, double-blind, placebo-controlled randomized clinical&#xD;
      trial of IBUD (50mg BID) for the treatment of Alcohol Use Disorder (AUD). The investigators&#xD;
      will randomize 132 treatment-seekers with current AUD over the course of 4 years. As a&#xD;
      behavioral support platform, all participants will complete the NIAAA-developed and&#xD;
      computer-delivered program &quot;Take Control&quot; during the study. Participants will complete&#xD;
      telephone screening, followed by in-person eligibility assessment, a physical exam for&#xD;
      medical eligibility, randomization to study medication or matched placebo, and in-person&#xD;
      follow-up visits at 4, 8, and 12 weeks of treatment. TLFB assessment of drinking outcomes&#xD;
      will also occur by telephone on weeks 2, 6, and 10. A final safety check visit will occur on&#xD;
      week 16, consisting of repeated clinical labs and ECG.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Two-Arm, Randomized, Double-Blind, Placebo-Controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent heavy drinking days</measure>
    <time_frame>12 week-treatment period</time_frame>
    <description>Heavy drinking days defined as 5+ drinks for men and 4+ for women</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Drinks per day</measure>
    <time_frame>12-week treatment period</time_frame>
    <description>secondary alcohol consumption endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drinks per drinking day</measure>
    <time_frame>12-week treatment period</time_frame>
    <description>secondary alcohol consumption endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent days abstinent</measure>
    <time_frame>12-week treatment period</time_frame>
    <description>secondary alcohol consumption endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent subjects with no heavy drinking days</measure>
    <time_frame>12-week treatment period</time_frame>
    <description>secondary alcohol consumption endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent subjects abstinent</measure>
    <time_frame>12-week treatment period</time_frame>
    <description>secondary alcohol consumption endpoint</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Depressive Symptomatology</measure>
    <time_frame>12-week treatment period</time_frame>
    <description>Responses from Beck Depression Inventory II (BDI-II) will be used to test this outcome</description>
  </other_outcome>
  <other_outcome>
    <measure>Neuroinflammation</measure>
    <time_frame>12-week treatment period</time_frame>
    <description>Blood levels of proinflammatory markers</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Alcohol Use Disorder</condition>
  <arm_group>
    <arm_group_label>Ibudilast</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10mg delayed-release capsules, target dose 50mg BID (5 x 10mg capsules twice daily) for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Oral Capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>matched to experimental drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibudilast</intervention_name>
    <description>targets neurotrophin signaling and neuroimmune function</description>
    <arm_group_label>Ibudilast</arm_group_label>
    <other_name>Pinatos</other_name>
    <other_name>MN-166</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>matched to active drug, ibudilast</description>
    <arm_group_label>Placebo Oral Capsule</arm_group_label>
    <other_name>Sugar Pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Be between the ages of 18 and 65&#xD;
&#xD;
          2. Meet current (i.e., past 12 months) DSM-5 diagnostic criteria for alcohol use disorder&#xD;
             moderate or severe&#xD;
&#xD;
          3. Be treatment-seeking for AUD&#xD;
&#xD;
          4. Report drinking at least 28 drinks per week if male (21 drinks per week if female) in&#xD;
             the 28 days prior to consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have a current (last 12 months) DSM-5 diagnosis of substance use disorder for any&#xD;
             psychoactive substances other than alcohol and nicotine&#xD;
&#xD;
          2. Have a lifetime DSM-5 diagnosis of schizophrenia, bipolar disorder, or any psychotic&#xD;
             disorder&#xD;
&#xD;
          3. Have a positive urine screen for narcotics, amphetamines, or sedative hypnotics;&#xD;
&#xD;
          4. Have clinically significant alcohol withdrawal symptoms as indicated by a score ≥ 10&#xD;
             on the Clinical Institute Withdrawal Assessment for Alcohol-Revised (CIWA-R)&#xD;
&#xD;
          5. Be pregnant, nursing, or planning to become pregnant while taking part in the study;&#xD;
             and must agree to one of the following methods of birth control (if female), unless&#xD;
             she or partner are surgically sterile:&#xD;
&#xD;
               -  Oral contraceptives&#xD;
&#xD;
               -  Contraceptive sponge&#xD;
&#xD;
               -  Patch&#xD;
&#xD;
               -  Double barrier&#xD;
&#xD;
               -  Intrauterine contraceptive device&#xD;
&#xD;
               -  Etonogestrel implant&#xD;
&#xD;
               -  Medroxyprogesterone acetate contraceptive injection&#xD;
&#xD;
               -  Complete abstinence from sexual intercourse&#xD;
&#xD;
               -  Hormonal vaginal contraceptive ring&#xD;
&#xD;
          6. Have a medical condition that may interfere with safe study participation (e.g.,&#xD;
             unstable cardiac, renal, or liver disease, uncontrolled hypertension or diabetes)&#xD;
&#xD;
          7. Have AST, ALT, or GGT ≥ 3 times upper normal limit&#xD;
&#xD;
          8. Have attempted suicide in the past 3 years and/or have had serious suicidal intention&#xD;
             or plan in the past year&#xD;
&#xD;
          9. Currently be on prescription medication that contraindicates use of IBUD, including&#xD;
             alpha or beta agonists, theophylline, or other sympathomimetic&#xD;
&#xD;
         10. Currently be on any medications for AUD or any psychotropic medications (e.g.,&#xD;
             psychostimulants and benzodiazepines) with the exception of stable antidepressants&#xD;
             (stable dose for ≥4 weeks)&#xD;
&#xD;
         11. Have any other circumstances that, in the opinion of the investigators, compromises&#xD;
             participant safety.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lara A. Ray, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jessica Jenkins, MS</last_name>
    <phone>310-206-6756</phone>
    <email>jenkinsj@ucla.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCLA Addictions Laboratory</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Jenkins, MA</last_name>
      <phone>310-206-6756</phone>
      <email>raylab@psych.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Lara Ray, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karen Miotto, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gang Li, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Irwin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steven Shoptaw, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>July 11, 2018</study_first_submitted>
  <study_first_submitted_qc>July 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2018</study_first_posted>
  <last_update_submitted>May 20, 2021</last_update_submitted>
  <last_update_submitted_qc>May 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Lara Ray, PhD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>ibudilast, treatment, medication development</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Alcohol Drinking</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibudilast</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

